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Abstract 
There is increasing recognition of the importance of patient’s perceptions of disease and their 
assessments of heath care processes. Patient-reported outcome measures (PROMs) are therefore 
now regarded as at least as important as the traditional objective measures of disease. For minors, 
parental and, except in the very young and severally cognitively impaired, the child’s perspectives 
are important because they provide unique and complementary information. In this review, we 
summarise the evidence on PROMs for allergy and asthma for use in children.  
 
Overall, there are fewer PROMs available for use in children than in adults. We were able to 
identify some validated pediatric PROMs that have been developed for use in atopic 
eczema/dermatitis, food allergy, allergic rhinitis/rhinoconjunctivitis and asthma. There is very 
limited evidence on deploying these instruments out with research settings.  There is therefore a 
pressing need to report on the experiences of using PROMs for allergy and asthma in routine 
clinical care. In particular, there is a need to understand how acceptable these are to 
children/carers, whether they can be incorporated into routine clinical assessments and if they are 
responsive to changes in treatment made in routine clinical practice. 
 
Introduction 
Over recent decades, there has been a major shift in clinicians and researchers’ understanding of 
the impact of disease and clinical interventions on patients (1, 2). Traditionally, this understanding 
was rooted in a ‘disease-centred’ paradigm, whereby the impact of diseases was primarily 
authenticated through objective measures and clinical criteria (1, 2). However, more recently, we 
have seen an important paradigm shift towards more patient-centred care (3). This new 
perspective emphasises the importance of subjective dimensions and patient perceived notions of 
disease and the impact of clinical interventions on their day-to-day well-being (1-3). There is now a 
greater recognition that disease and the clinical encounter are perceived not only in terms of 
objective targets, but that these need to be understood together with patients’ perceptions of their 
condition, which are influenced and/or reinforced by their beliefs, experiences and cultural realities 
(1-3). Consequently, the outcomes of clinical interventions obtained based on patient reports 
without involvement or interpretation of a physician, commonly known as patient-reported outcome 
measures (PROMs), should be considered as at least as important as more traditional objective 
assessments (1, 4).  
 
In this paper, drawing on our recent rigorously conducted systematic reviews, systematic reviews 
from other investigators, and key recent evidence-based guidelines from the European Academy of 
Allergy and Clinical Immunology (EAACI) and the Global Allergy and Asthma European Network 
(G 2LEN), we provide an overview of the current evidence on PROMs for allergy and asthma in 
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atopic eczema, food allergy, allergic rhinitis and asthma. We have deliberately steered clear of 
discussing PROMs that have not been validated as these may not accurately reflect patient 
perceptions of their conditions. We highlight the key features of these validated instruments and 
discuss future developments that may enhance their usefulness. 
 
Definition of PROMs 
There is no universally accepted definition of PROMs, but we will here adopt a definition we had 
earlier proposed (see Box 1) (6). PROMs are used to assess a range of outcomes primarily from 
clinical trials assessing the impact of illness or clinical interventions; these include health or 
functional status, health-related quality of life, perception of symptoms, well-being, satisfaction with 
treatment, and perceptions of the quality of care (6, 9).  
 
The importance of PROMs in the context of allergy and asthma 
The importance of collecting data on PROMs during clinical trials and, more recently, routine 
clinical encounters has been advocated by leading global health institutions, including the World 
Health Organization (WHO), the United States Food and Drug Administration (FDA), and the 
European Medicines Agency (EMEA) (3, 10, 11).  
 
Asthma is now the commonest long-term condition among children (12). Together with other 
allergic disorders, such as atopic eczema/dermatitis, allergic rhinitis, food allergy and asthma, 
these conditions constitute a considerable burden on the daily lives of many children and their 
families (13). In addition, whilst several therapeutic regimens have been developed to manage 
allergic disorders and asthma, adherence to recommended regimens may also have substantial 
impact on the day-to-day lived experience of children and their parent/caregivers (5). For example, 
decisions surrounding the use of adrenaline (epinephrine) in the context of managing anaphylaxis 
or inhalers for asthma control may have a negative impact on the child or their parents/caregivers 
(5). Capturing children’s or parents’/caregivers’ perception of the impact of allergic disorders and 
asthma and the impact of treatments will help support improved decision-making by clinicians and 
help researchers better design interventions that target improvement of the overall quality of life of 
children and their families (1, 5, 6). The World Allergy Organization (WAO), EAACI and GA2LEN 
therefore now also recommend that PROMs should be routinely collected in allergy and asthma 
clinical trials (1, 7).  
 
Generic and disease-specific instrument 
Over 3,000 generic and disease-specific PROMs currently exist, these now commonly being used 
in research, particularly in clinical trials (6). Generic PROMs are instruments that assess patients’ 
perception across a number of diseases at the same time without having a particular disease as 
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one specific disease. Whilst generic PROMs may allow comparison of patient perceptions across 
different diseases, unlike disease-specific PROMs they do not allow detailed picture of patient 
perceptions of specific diseases to emerge; furthermore, they typically fail to capture changes in 
patients’ everyday concerns related to their disease status (1, 5, 6). An additional advantage of 
disease-specific PROMs over generic PROMs is that they are more sensitive in estimating the 
burden of disease and capturing the impact of interventions (1, 5, 14). 
 
Existing validated disease-specific PROMs for allergy and asthma in children 
Most existing validated disease-specific PROMs for allergy and asthma have been developed for 
the adult population. Key features of the available validated disease-specific PROMs for allergy 
and asthma in children are summarized in Table 1.  
 
PROMs for atopic eczema/dermatitis in children 
A recent systematic review identified one validated PROM for children with atopic 
eczema/dermatitis: the Infant’s Dermatitis Quality of Life Index (IDQoL) (8). This tool was 
developed in 2001 and it is intended to be completed by parents or caregivers to assess the impact 
of atopic dermatitis on the Quality of Life (QOL) of children below the age of four years (15, 16). 
The IDQoL has been extensively validated and used in several studies, now translated into 21 
languages and used in 18 countries; it contains 10 questions, each question scoring a minimum of 
zero and maximum of three.  
 
PROMs for food allergy in children 
From our previous systematic review (5), which contributed to the development of the EAACI 
guideline on food allergy health related QOL measures (7), we identified three core food allergy-
specific PROMs for the pediatric population, all measuring the QOL of children with food allergy.  
These have been validated in several studies (5). The instruments are: (a) Food Allergy Quality of 
Life Questionnaire (FAQLQ); (b) Food Allergy Quality of Life Assessment Tool for Adolescents 
(FAQL-teen); and (c) You and Your Food Allergy. The detail appraisal of these instruments and the 
results of the studies validating their performance are presented in that review (5). The FAQLQ 
instrument was originally developed in Dutch.  It is divided into two: FAQLQ-Child Form and 
FAQLQ-Teenager Form. The FAQLQ-Child Form is intended for children aged 8-12 years and 
contains 24 self-reported items and four domains. The FAQLQ-Teenager Form is intended for 
children aged 13-17 years and contains 28 self-reported items and three domains. The FAQL-teen 
instrument was developed in the United States and intended for children aged 13-19 years; it 
contains 17 self-reported items. You and Your Food Allergy instrument was developed in the UK 
for children aged 13-18 years, containing 34 self-reported items, which are divided into five 
domains (5). 
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We identified two validated disease-specific PROMs for assessment of disease-specific QOL in 
children with allergic rhinitis or rhinoconjunctivitis: (a) the Pediatric Rhinoconjunctivitis Quality of 
Life Questionnaire (PRQLQ)(17) and (b) the Adolescent Rhinoconjunctivitis Quality of Life 
Questionnaire (AdolRQLQ) (18). Both PRQLQ and AdolRQLQ were original developed to be 
applied in North America. The PRQLQ contains 23 question items in five domains and it is 
intended to be self-completed by children aged 6-12 years. The AdolRQLQ contains 25 question 
items in six domains and it is intended to be self-completed by children aged 12-17 years 
 
PROMs for asthma in children 
For asthma, our previous systematic review identified four validated asthma-specific PROMs for 
children (6). These include: (a) the Pediatric Asthma Quality of Life Questionnaire (PAQLQ); (b) 
Childhood Asthma Control Test (C-ACT); (c) Childhood Asthma Questionnaire (CAQ); and (d) 
Pediatric Asthma Quality of Life (PedsQL). Our detailed appraisals of these instruments are 
presented in that paper (6). 
 
The PAQLQ is derived from the Asthma Quality of Life Questionnaire (AQLQ) originally designed 
for use in adults (19, 20); it is intended to measure the functional impairments of children with 
asthma. Although our appraisal showed that only few validation studies have been undertaken to 
assess the validity of PAQLQ, it is the only PROM that comprehensively addresses asthma-related 
QOL in children with asthma.  
 
The C-ACT measures the degree of asthma control in children and our appraisal indicated that 
although it offers promise for this purpose, further validation work is required to be undertaken 
considering concerns about whether it adequately measures poorly controlled asthma (6). The 
CAQ was developed to measure the quality of life of children with asthma, but our appraisal 
showed that it has been poorly validated (6).  
 
The PedsQL is a generic instrument but has disease-specific modules, including a module for 
asthma, which is also intended to measure the QOL in children with asthma. Our appraisal 
indicated that the development of the PedsQL was inadequate and there was wide variation in its 
performance; the asthma module was particularly poorly described, thus its application for 
assessing the QOL of children with asthma appears largely inadequate (6).  
 
Challenges of incorporating PROMs into routine care and areas for further research and 
development 
Most of the evidence in relation to use of PROMs in the context of allergy and asthma in children 
comes from clinical research studies.  There is therefore very little evidence in relation to their 
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relate to awareness of which validated instruments are available, which to select when a choice 
exists, the frequency with which these should be used, the burden on children/carers associated 
with completing these, and how best to incorporate the findings from these instruments into routine 
care (22-24). There is therefore the need for important health services research to provide answers 
to these and related questions pertaining to routine clinical use of allergy and asthma PROMs in 
children.   
 
Moreover, there is a need to ensure that there is a comprehensive suite of PROMs available for 
use across the range of clinical presentations of allergy in children, and that these are available 
both for completion by affected children and carers. There is therefore the need for further 
development work in relation to conditions such as venom allergy, urticaria and angioedema.  It is 
also important that these tools are available across all childhood age groups and in a range of 
languages suitable for use in multicultural populations. 
 
Conclusions  
Whilst there is an increasing recognition of the importance of integrating PROMs in clinical practice 
and as part of the outcomes assessed when evaluating the impact of diseases and clinical 
interventions in clinical research, progress has been slow in incorporating PROMs for allergy and 
asthma into the routine clinical care of children.  We have in this paper identified available 
validated PROMs for use in children and summarized their key properties (Table 1).  This we hope 
should provide both physicians and researchers an accessible summary of the available 
instruments and whom it is appropriate to use these in. We have also through so doing highlighted 
gaps where no suitable instruments exist, and these should be seen as priority areas for further 
development.  More generally, we have highlighted the need for a focused effort on developing the 
evidence base in relation to the opportunities and challenges with deploying PROMs for allergy 
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Box 1: Definition of a PROM (6) 
 
“A PROM for a long-term condition is a measure of the impact and/or the outcome of 
treatment for that condition on a patient’s quality of life, reported directly by the patient or 
carer. This may include impact of the condition on health-related quality of life, 
perceptions of health/functional status related to the long-term condition and the impact 
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Table 1 Characteristics of existing validated patient reported outcome measures (PROMs) for allergy and asthma in children 
Instrument Target population Number of items and 
domains 





PROM for atopic eczema/dermatitis 
Infant’s Dermatitis Quality of 
Life Index (IDQoL) 
Children with atopic eczema/dermatitis 
below the aged of 4 years 




2-3 min English 
 
PROMs for food allergy 
 
Food Allergy Quality of Life 
Questionnaire (FAQLQ): 
  FAQLQ-Child Form 
(FAQLQ-CF) 
  FAQLQ-Teenager Form 
(FAQLQ-TF) 
FAQLQ-CF for children aged 8-12 
years 
FAQLQ-TF for adolescents aged 13-
17 years 
FAQLQ-CF: 24 items in four 
domains: allergen 
avoidance; risk of accidental 
exposure; emotional impact; 
and dietary restrictions 
FAQLQ-TF: 28 items in 
three domains: allergen 
avoidance and dietary 
restrictions; emotional 
impact; and risk of 
accidental exposure  
FAQLQ-CF: self-
completed by child 
FAQLQ-TF: self-complete 
by adolescent 
Not indicated Dutch 
Food Allergy Quality of Life 
Assessment Tool for 
Adolescents (FAQL-teen) 
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Instrument Target population Number of items and 
domains 




You and Your Food Allergy Teenagers aged 13-18 years 34 items in five domains: 
social well-being and 
independence; support; 
day-to-day activities; family 




Not indicated English  
 
PROMs for allergic rhinitis/rhinoconjunctivitis 
Pediatric Rhinoconjunctivitis 
Quality of Life Questionnaire 
(PRQLQ)  
Children with allergic 
rhinitis/rhinoconjunctivitis aged 6-12 
years 
23 items in 5 domains: nose 
symptoms, eye symptoms, 
practical problems, activity 
limitation and other 
symptoms 
Self-completed Not indicated English 
Adolescent 
Rhinoconjunctivitis Quality of 
Life Questionnaire 
(AdolRQLQ). 
Children with allergic 
rhinitis/rhinoconjunctivitis aged 12-17 
years 
25 items in six domains: 
nose symptoms, eye 
symptoms, practical 
problems, activity limitation, 
non-hayfever symptoms and 
emotional function 
Self-completed Not indicated English 
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Instrument Target population Number of items and 
domains 




Pediatric Asthma Quality of 
Life Questionnaire (PAQLQ) 
Children with asthma aged 7-17 years 23 items in 3 domains: 10 
items for symptoms 
5 items for activity 




10-15 min English 
Childhood Asthma Control 
Test (C-ACT)   
Children with asthma aged 4-11 years 7 items in 2 domains: 
4 items for child 
3 items for caregiver 
Self-completed (child), and 
caregiver 
Not indicated English 
Childhood Asthma 
Questionnaire (CAQ); 
CAQ-A children 4-7 years 
CAQ-B children 8-11 years 
CAQ-C children 12-16 years 
CAQ-A 14 items, domains 
not indicated 
CAQ-B 23 items, domains 
not indicated 
CAQ-C 46 items, domains 
not indicated 
Self-completed, with 
parental assistance if 
required 
10-20 min English 
PedsQL Children and adolescents aged 2-18 
years 
Generic core: 23 items in 4 
domains 
Asthma module: 28 items in 
4 domains: 
11 items for symptoms 
11 items for treatment 
problems 
3 items for worry 
3 items for communication 
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